Is CNTB or GRCE more profitable?

Grace Therapeutics' return on equity of -15.58% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Connect Biopharma N/A -122.29% -97.07% Grace Therapeutics N/A -15.58% -14.51%

Does the media favor CNTB or GRCE?

In the previous week, Connect Biopharma and Connect Biopharma both had 2 articles in the media. Connect Biopharma's average media sentiment score of 1.68 beat Grace Therapeutics' score of 1.17 indicating that Connect Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Grace Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, HURA or GRCE?

Grace Therapeutics is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TuHURA Biosciences N/A N/A -$30.05M -$0.61 N/A Grace Therapeutics N/A N/A -$9.57M -$0.40 N/A

Is HURA or GRCE more profitable?

Grace Therapeutics' return on equity of -15.58% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.12% -105.38% Grace Therapeutics N/A -15.58% -14.51%

Does the media favor HURA or GRCE?

In the previous week, TuHURA Biosciences had 10 more articles in the media than Grace Therapeutics. MarketBeat recorded 12 mentions for TuHURA Biosciences and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.17 beat TuHURA Biosciences' score of -0.05 indicating that Grace Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Grace Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, CRDL or GRCE?

Grace Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.28 N/A Grace Therapeutics N/A N/A -$9.57M -$0.40 N/A

Is CRDL or GRCE more profitable?

Grace Therapeutics' return on equity of -15.58% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -229.43% -165.60% Grace Therapeutics N/A -15.58% -14.51%

Does the media refer more to CRDL or GRCE?

In the previous week, Grace Therapeutics had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 2 mentions for Grace Therapeutics and 1 mentions for Cardiol Therapeutics. Grace Therapeutics' average media sentiment score of 1.17 beat Cardiol Therapeutics' score of 0.93 indicating that Grace Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grace Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, CRBP or GRCE?

Grace Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corbus Pharmaceuticals N/A N/A -$78.54M -$5.82 N/A Grace Therapeutics N/A N/A -$9.57M -$0.40 N/A

Is CRBP or GRCE more profitable?

Grace Therapeutics' return on equity of -15.58% beat Corbus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corbus Pharmaceuticals N/A -70.89% -61.78% Grace Therapeutics N/A -15.58% -14.51%

Does the media favor CRBP or GRCE?

In the previous week, Corbus Pharmaceuticals had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 5 mentions for Corbus Pharmaceuticals and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.17 beat Corbus Pharmaceuticals' score of 0.61 indicating that Grace Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Grace Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GRCE or GNLX more profitable?

Grace Therapeutics' return on equity of -15.58% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -15.58% -14.51% Genelux N/A -174.55% -123.65%

Does the media refer more to GRCE or GNLX?

In the previous week, Grace Therapeutics and Grace Therapeutics both had 2 articles in the media. Grace Therapeutics' average media sentiment score of 1.17 beat Genelux's score of 0.91 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genelux 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Grace Therapeutics (GRCE) Competitors

$2.40 -0.05 (-1.84%)

Closing price 03:58 PM Eastern

Extended Trading

$2.42 +0.02 (+0.62%)

As of 04:28 PM Eastern

Compare

GRCE vs. CNTB, HURA, CRDL, CRBP, and GNLX

Should you buy Grace Therapeutics stock or one of its competitors? MarketBeat compares Grace Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Grace Therapeutics include Connect Biopharma (CNTB), TuHURA Biosciences (HURA), Cardiol Therapeutics (CRDL), Corbus Pharmaceuticals (CRBP), and Genelux (GNLX). These companies are all part of the "pharmaceutical products" industry.

How does Grace Therapeutics compare to Connect Biopharma?

Connect Biopharma (NASDAQ:CNTB) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Connect Biopharma presently has a consensus target price of $7.20, suggesting a potential upside of 213.04%. Grace Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 149.48%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Connect Biopharma is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Grace Therapeutics' return on equity of -15.58% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-122.29%	-97.07%
Grace Therapeutics	N/A	-15.58%	-14.51%

Connect Biopharma has a beta of -0.22, meaning that its share price is 122% less volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

In the previous week, Connect Biopharma and Connect Biopharma both had 2 articles in the media. Connect Biopharma's average media sentiment score of 1.68 beat Grace Therapeutics' score of 1.17 indicating that Connect Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Grace Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by insiders. Comparatively, 11.1% of Grace Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Grace Therapeutics has lower revenue, but higher earnings than Connect Biopharma. Grace Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,413.47	-$55.48M	-$1.15	N/A
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A

Summary

Connect Biopharma beats Grace Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Grace Therapeutics compare to TuHURA Biosciences?

TuHURA Biosciences (NASDAQ:HURA) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

In the previous week, TuHURA Biosciences had 10 more articles in the media than Grace Therapeutics. MarketBeat recorded 12 mentions for TuHURA Biosciences and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.17 beat TuHURA Biosciences' score of -0.05 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grace Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TuHURA Biosciences currently has a consensus price target of $9.00, suggesting a potential upside of 310.96%. Grace Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 149.48%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe TuHURA Biosciences is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

TuHURA Biosciences has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

Grace Therapeutics is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by company insiders. Comparatively, 11.1% of Grace Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Grace Therapeutics' return on equity of -15.58% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
Grace Therapeutics	N/A	-15.58%	-14.51%

Summary

Grace Therapeutics beats TuHURA Biosciences on 8 of the 13 factors compared between the two stocks.

How does Grace Therapeutics compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Grace Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 11.1% of Grace Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cardiol Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

Cardiol Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 639.13%. Grace Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 149.48%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cardiol Therapeutics is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Grace Therapeutics' return on equity of -15.58% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Grace Therapeutics	N/A	-15.58%	-14.51%

In the previous week, Grace Therapeutics had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 2 mentions for Grace Therapeutics and 1 mentions for Cardiol Therapeutics. Grace Therapeutics' average media sentiment score of 1.17 beat Cardiol Therapeutics' score of 0.93 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grace Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cardiol Therapeutics beats Grace Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Grace Therapeutics compare to Corbus Pharmaceuticals?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Corbus Pharmaceuticals had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 5 mentions for Corbus Pharmaceuticals and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.17 beat Corbus Pharmaceuticals' score of 0.61 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corbus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Grace Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grace Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A

Corbus Pharmaceuticals currently has a consensus target price of $42.00, suggesting a potential upside of 425.00%. Grace Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 149.48%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Corbus Pharmaceuticals is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Corbus Pharmaceuticals has a beta of 2.57, indicating that its stock price is 157% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

Grace Therapeutics' return on equity of -15.58% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
Grace Therapeutics	N/A	-15.58%	-14.51%

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 11.1% of Grace Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Corbus Pharmaceuticals beats Grace Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Grace Therapeutics compare to Genelux?

Grace Therapeutics (NASDAQ:GRCE) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

In the previous week, Grace Therapeutics and Grace Therapeutics both had 2 articles in the media. Grace Therapeutics' average media sentiment score of 1.17 beat Genelux's score of 0.91 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genelux	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grace Therapeutics has higher earnings, but lower revenue than Genelux. Grace Therapeutics is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A
Genelux	$10K	13,810.72	-$32.15M	-$0.85	N/A

Grace Therapeutics has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Genelux has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 11.1% of Grace Therapeutics shares are held by company insiders. Comparatively, 7.5% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Grace Therapeutics' return on equity of -15.58% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-15.58%	-14.51%
Genelux	N/A	-174.55%	-123.65%

Grace Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 149.48%. Genelux has a consensus price target of $18.00, suggesting a potential upside of 484.42%. Given Genelux's stronger consensus rating and higher probable upside, analysts clearly believe Genelux is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Genelux beats Grace Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Grace Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRCE vs. The Competition

Export

Metric	Grace Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$37.21M	$3.34B	$6.44B	$12.46B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-6.01	18.78	23.87	24.36
Price / Sales	N/A	320.80	521.52	117.07
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	0.49	6.80	9.99	6.73
Net Income	-$9.57M	$24.09M	$3.56B	$337.03M
7 Day Performance	-1.03%	-2.56%	-0.89%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-16.49%	48.90%	28.77%	33.98%

Grace Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRCE Grace Therapeutics	2.6709 of 5 stars	$2.41 -1.8%	$6.00 +149.5%	-13.1%	$37.21M	N/A	N/A	N/A	News Coverage
CNTB Connect Biopharma	3.8384 of 5 stars	$2.49 +4.6%	$7.20 +189.2%	+175.0%	$149.85M	$60K	N/A	110	Insider Trade
HURA TuHURA Biosciences	1.886 of 5 stars	$2.26 -3.8%	$9.00 +298.2%	-27.6%	$149.65M	N/A	N/A	N/A	Analyst Revision Gap Down
CRDL Cardiol Therapeutics	2.3585 of 5 stars	$1.22 -4.7%	$8.50 +596.7%	-14.5%	$143.13M	N/A	N/A	20	Positive News
CRBP Corbus Pharmaceuticals	4.5243 of 5 stars	$7.91 +3.5%	$42.00 +431.0%	-11.1%	$141.55M	N/A	N/A	40	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRCE) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Grace Therapeutics (GRCE) Competitors

GRCE vs. CNTB, HURA, CRDL, CRBP, and GNLX

How does Grace Therapeutics compare to Connect Biopharma?

Summary

How does Grace Therapeutics compare to TuHURA Biosciences?

Summary

How does Grace Therapeutics compare to Cardiol Therapeutics?

Summary

How does Grace Therapeutics compare to Corbus Pharmaceuticals?

Summary

How does Grace Therapeutics compare to Genelux?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE vs. The Competition

Grace Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Grace Therapeutics (GRCE) Competitors

GRCE vs. CNTB, HURA, CRDL, CRBP, and GNLX

How does Grace Therapeutics compare to Connect Biopharma?

Do analysts recommend CNTB or GRCE?

Is CNTB or GRCE more profitable?

Which has more volatility and risk, CNTB or GRCE?

Does the media favor CNTB or GRCE?

Do insiders & institutionals hold more shares of CNTB or GRCE?

Which has stronger earnings & valuation, CNTB or GRCE?

Summary

How does Grace Therapeutics compare to TuHURA Biosciences?

Does the media favor HURA or GRCE?

Do analysts rate HURA or GRCE?

Which has more volatility and risk, HURA or GRCE?

Which has better valuation and earnings, HURA or GRCE?

Do insiders and institutionals hold more shares of HURA or GRCE?

Is HURA or GRCE more profitable?

Summary

How does Grace Therapeutics compare to Cardiol Therapeutics?

Which has preferable earnings and valuation, CRDL or GRCE?

Do institutionals & insiders hold more shares of CRDL or GRCE?

Which has more risk and volatility, CRDL or GRCE?

Do analysts prefer CRDL or GRCE?

Is CRDL or GRCE more profitable?

Does the media refer more to CRDL or GRCE?

Summary

How does Grace Therapeutics compare to Corbus Pharmaceuticals?

Does the media favor CRBP or GRCE?

Which has preferable valuation & earnings, CRBP or GRCE?

Do analysts rate CRBP or GRCE?

Which has more volatility & risk, CRBP or GRCE?

Is CRBP or GRCE more profitable?

Do institutionals and insiders hold more shares of CRBP or GRCE?

Summary

How does Grace Therapeutics compare to Genelux?

Does the media refer more to GRCE or GNLX?

Which has better earnings & valuation, GRCE or GNLX?

Which has more volatility & risk, GRCE or GNLX?

Do insiders and institutionals hold more shares of GRCE or GNLX?

Is GRCE or GNLX more profitable?

Do analysts prefer GRCE or GNLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE vs. The Competition

Grace Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools